NHS England strikes deal to make innovative Multiple Sclerosis drug available, paving the way for NICE recommendation
Patients with Multiple Sclerosis (MS) will have routine access to a drug that can slow disability under a deal struck between NHS England and the manufacturer Roche, paving the way for its approval by NICE.
Ocrelizumab (also known as Ocrevus) is the first treatment that can modify or change the course of the disease to be available for patients who have primary progressive multiple sclerosis, where symptoms steadily increase over a period of months or years without periods of remission.
Clinical trial results show that ocrelizumab can slow the worsening of disability in people with the condition, helping patients stay able and active for longer.
Giving patients access to world class, cutting edge drugs and therapies is a key part of the NHS Long Term Plan.
Simon Stevens, chief executive of NHS England said:
“Today the NHS is making a significant advance in the care of people living with multiple sclerosis. This latest innovative deal is further proof that companies willing to work flexibly with the NHS can secure a constructive partnership that benefits both patients and taxpayers.”
The innovative deal between NHS England and Roche unlocks the final stage of NICE’s appraisal and opens the way for access to this important treatment.
It is estimated that 10,000-15,000 people have Primary progressive MS (PPMS) in the UK, of whom around 2,700 people could be eligible for treatment with ocrelizumab.
Multiple sclerosis is a lifelong condition which affects the brain and spinal cord. It affects everyone differently and there are a wide range of possible symptoms.
Primary progressive MS can have a substantial impact on the lives of people with the condition and their families.
Ocrelizumab will now be routinely available for eligible adults which, given the lack of other treatments for this form of MS, is great news for patients.
Ocrelizumab is given as an infusion during an outpatient appointment once every six months and costs around £19,000 per patient per year at full price.
NHS England has secured a commercial in confidence deal with Roche after tough negotiations on both sides.
With the deal, the cost-effectiveness estimates for ocrelizumab are in the range that NICE considers an acceptable use of NHS resources.
Previous arrangements would be down to industry proposing a price where NICE say yes or no to the drug being made available. NHS England now has more direct involvement with industry, working closely with NICE, to help to find deals that work for patients and taxpayers.
Latest News from
NHS invests £5 million to improve care for people with a learning disability21/05/2019 15:15:00
The NHS has today announced that an additional £5 million will fund reviews to improve care for people with a learning disability and committed to renewed national action to tackle serious conditions.
National Heroes Service: GPs told ‘our veterans need you’20/05/2019 14:15:00
NHS chiefs have urged family doctors to enlist in a scheme improving care for thousands of armed forces veterans and their families.
NHS England to fund first ever treatment for children with rare muscle-wasting condition16/05/2019 09:15:00
NHS England will provide a promising new treatment which can prolong the lives of children with a rare genetic condition after negotiating a deal with the manufacturer.
NHS funds tech to protect prostate cancer patients during radiation treatment14/05/2019 09:15:00
An innovation that can reduce the side-effects of radiotherapy for prostate cancer patients by over 70 per cent will be rolled out across the NHS, as part of the Long Term Plan to put cutting-edge treatments at the heart of people’s care.
Army of NHS experts brought in to care homes to tackle over-medication13/05/2019 09:15:00
An army of experts have been recruited by NHS England to help prevent care home residents being given too many medicines as part of a package of measures to improve older people’s health and care in the NHS Long Term Plan.
NHS England funds £2million to boost system-wide leadership development09/05/2019 09:15:00
NHS England has funded a £2million programme to help 23 areas kick-start or boost leadership development activities to support and inspire workforce in health systems across England from GPs, consultants and therapists to nurses, social workers and managers.
NHS funds handheld headache-busting device as part of Long Term Plan08/05/2019 09:15:00
A device that can zap away excruciating headaches is to receive NHS England funding from a scheme that helps to spread the use of world-leading technology across the health service.
NHS Stroke action will save hundreds of lives07/05/2019 15:38:00
A new £9 million programme to spot heart conditions earlier will save at least 200 lives and offer protection to thousands more, NHS England announced today.
NHS Long Term Plan to give mums the ‘Royal Treatment’, as 14,000 choose home birth07/05/2019 13:15:00
Almost 14,000 families have opted for a home birth in a single year, which might include the Duke and Duchess of Sussex, as mothers-to-be are offered greater choice over the care they receive thanks to the NHS Long Term Plan.